Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more.
Almac reported a 14% increase in its revenue last year, reaching £958 million ($1.2 billion), up from 2022’s £840 million ($1.1 billion). Nonetheless, the CDMO’s 2023 profit was down slightly by 3% at £93.8 million ($119.2 million) from £97 million ($123 million) in 2022, according to a Tuesday release.
The European Commission approved the French government’s €4 billion ($4.3 billion) investment into reducing greenhouse gasses in the manufacturing sector, according to a May 24 announcement. An EC spokesperson told Endpoints this effort also covers the manufacturing of basic pharmaceuticals.
Four manufacturers — ScaleReady, Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady — have launched a $20 million program to advance cell and gene therapy production. The G-Rex Grant Program will offer services in process development and manufacturing for pre-clinical assets, according to a Wednesday press release.
CDMO ProBioGen is collaborating with ModeX Therapeutics, with the manufacturer to develop and make the biotech’s clinical-stage Covid-19 antibody, according to a Wednesday announcement.
Cell and gene therapy manufacturer Cellular Origins and UK industry body CGT Catapult have partnered to show the benefits of automating CGT production. CGT Catapult will use the manufacturer’s robotic platform, dubbed Constellation, to do so, they said in a Wednesday release.
T cell engineering company Anocca and stem cell therapy developer Shinobi Therapeutics are partnering to develop an allogeneic T cell therapy using pluripotent stem cells for solid tumors, according to a Thursday release.
Eurofins CDMO Alphora expanded its laboratory in Mississauga, Canada. The expansion adds specialized equipment such as a new suite for liquid chromatography, gas chromatography and abilities to measure water activity, according to a Wednesday release.
The National Institute for Bioprocessing Research and Training opened its new facility in Dublin, Ireland, for cell therapies, gene therapies, mRNA and DNA-based therapies, and biologics, according to a May 23 release.
Cell and gene CDMO Andelyn Biosciences was selected by the California Institute for Regenerative Medicine to upscale and produce large volumes of adeno-associated vector therapies for type 1 congenital hereditary endothelial dystrophy, according to a May 23 release.